Literature DB >> 25518360

[Treatment for high-risk localized prostate cancer].

Shintaro Narita, Norihiko Tsuchiya, Tomonori Habuchi.   

Abstract

High-risk localized prostate cancer encompasses a significant heterogeneity and the treatment strategy for this group of prostate cancer patients remains controversial. The definition of high-risk localized prostate cancer is not consistent in that which clinicopathological parameters are included as risk factors. Therefore, we need to be careful in comparing the treatment outcome of each report. Recently, there have been significant improvements in the radiotherapeutic and surgical management. High radiation dose levels, long-term androgen deprivation therapy, and the combination of brachytherapy may contribute to the improvement of radiation-based treatment. Although some patients can be cured by standard surgical approach, extended lymph node dissection and multimodal treatment with radiation and chemohormonal therapy may improve surgical outcome. This review focuses on the recent treatment strategy for high-risk localized prostate cancer.

Entities:  

Mesh:

Year:  2014        PMID: 25518360

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  1 in total

1.  GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.

Authors:  Fang Liang; Junmin Yue; Junyong Wang; Lijuan Zhang; Rui Fan; Hao Zhang; Qingsong Zhang
Journal:  Med Oncol       Date:  2015-01-31       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.